Literature DB >> 30133790

What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.

Sachin Malde1, Christopher Fry2, Brigitte Schurch3, Tom Marcelissen4, Marcio Averbeck5, Alex Digesu6, Arun Sahai1,7.   

Abstract

AIMS: Botulinum toxin A (BTX-A) and sacral nerve stimulation (SNS) are established treatments for overactive bladder (OAB) and are standard of care in refractory cases in international guidelines. Despite long term use over decades their "exact" working mechanisms are not entirely clear. At the ICI-RS meeting in Bristol in 2017 a think tank was convened to address the question.
METHODS: The think tank conducted a literature review and an expert consensus meeting focusing on current mechanisms and what could be learned from clinical experience and objective urodynamic data.
RESULTS: BTX-A results suggests effects on both filling and voiding parts of the micturition cycle. The salient data in this regard is presented as well as additional studies related to the urothelium and evidence for central effects. Urodynamics have consistently shown increases in bladder capacity, compliance, and reductions in detrusor pressures during filling, however post void residuals also increase in a dose-dependent fashion. During SNS activation of somatic afferents inhibits bladder sensory pathways and reflex bladder hyperactivity. Evidence in cats suggest the inhibition of bladder activity occurs primarily in the CNS by inhibition of the ascending or descending pathways of the spinobulbospinal micturition reflex. Urodynamics have suggested improvement in bladder capacity and reduction in detrusor pressures during filling with little observed effects on voiding parameters.
CONCLUSIONS: The working mechanism of BTX-A and SNS is complex. The exact mechanisms are still unknown, although considerable progress has been made in our understanding. Further research proposals are suggested to help further elucidate these mechanisms.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Botox; botulinum toxin; detrusor overactivity; interstim; mechanism of action; onabotulinumtoxinA; overactive bladder; sacral nerve stimulation; sacral neuromodulation; urodynamics

Mesh:

Substances:

Year:  2018        PMID: 30133790     DOI: 10.1002/nau.23552

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  3 in total

1.  Evaluation of the effect of 100U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: A multicentre prospective study.

Authors:  Gaetano De Rienzo; Paolo Minafra; Ester Iliano; Enrico Finazzi Agrò; Maurizio Serati; Alessandro Giammò; Francesco Paolo Bianchi; Elisabetta Costantini; Pasquale Ditonno
Journal:  Neurourol Urodyn       Date:  2021-10-19       Impact factor: 2.367

2.  Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation.

Authors:  Hamilton Trinh; Vicki Irish; Mireya Diaz; Humphrey Atiemo
Journal:  Int Neurourol J       Date:  2019-09-30       Impact factor: 2.835

Review 3.  The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin.

Authors:  Chiara Traini; Maria Giuliana Vannucchi
Journal:  Toxins (Basel)       Date:  2019-10-24       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.